Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patients With RA May Not Change Therapies for Treat-to-Target

In an analysis of national RISE registry data, one- to two-thirds of patients with rheumatoid arthritis (RA) failed the change their treatment, even when in moderate or high disease activity. Eligible patients were identified as follows: 1) age ≥18 years; 2) RA diagnoses; 3) ≥2 RISE visits; 4) ≥1 RA disease activity measure in 2016. Outcomes included change in treatment over 12 months. Researchers found:

  • Among 50,996 eligible patients, 27,274 were with longitudinal data.
  • Commonly used measures were RAPID3 and CDAI.
  • The frequency of treatment change during follow-up was relatively low, even for patients in moderate or high disease activity by RAPID3 or CDAI.
  • Older patients and those already receiving combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or combo therapy with biologic disease-modifying antirheumatic drugs (bDMARDs) were less likely to change RA treatment.


Yun H, et al. Do patients with moderate or high disease activity escalate RA therapy according to treat-to-target principles? Results from the ACR’s RISE registry. [Published online ahead of print September 30, 2019]. Arthritis Care Res. doi: 10.1002/acr.24083.